366 results
Page 2 of 19
8-K
2hzcvxtc9u
14 Nov 22
ImmunoGen Announces FDA Accelerated Approval of ELAHEREā¢ (mirvetuximab soravtansine-gynx) for the Treatment of Platinum-Resistant Ovarian Cancer
5:23pm
8-K
EX-99.1
y08g8eshjaf 6wwfwq30
14 Nov 22
ImmunoGen Announces FDA Accelerated Approval of ELAHEREā¢ (mirvetuximab soravtansine-gynx) for the Treatment of Platinum-Resistant Ovarian Cancer
5:23pm
S-8
EX-23.1
rp523
1 Aug 22
Registration of securities for employees
5:29pm
S-8
EX-5.1
kak7rumxj
1 Aug 22
Registration of securities for employees
5:29pm
S-8
EX-23.1
eqs2o9j w1lh
1 Aug 22
Registration of securities for employees
5:29pm
S-8
EX-5.1
63fgsnbv
1 Aug 22
Registration of securities for employees
5:29pm
8-K
9xgmigv
17 Jun 22
Departure of Directors or Certain Officers
5:07pm
8-K
EX-99.1
a9sx42is
6 May 22
ImmunoGen Reports Recent Progress and First Quarter 2022 Financial Results
6:41am
DEFA14A
sqt558h
26 Apr 22
Additional proxy soliciting materials
5:23pm
8-K
EX-99.1
ob9l4d
10 Jan 22
Results of Operations and Financial Condition
7:30am